Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedJun 5, 2013PGE-1 Inj 10mcg/ml MDVLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.Nora Apothecary and Alternative Therapies, Inc. · D-457-2013Class IITerminatedJun 5, 2013Papaverine Inj 30mg/ml SyrLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.Nora Apothecary and Alternative Therapies, Inc. · D-456-2013Class IITerminatedJun 5, 2013Bimix Inj 30:1 MDV: 5mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.Nora Apothecary and Alternative Therapies, Inc. · D-455-2013Class IITerminatedJun 5, 2013Bimix Inj 30:0.5 MDVLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.Nora Apothecary and Alternative Therapies, Inc. · D-454-2013Class IITerminatedJun 5, 2013Bimix Inj 30 :1 SyrLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.Nora Apothecary and Alternative Therapies, Inc. · D-453-2013Class IIITerminatedMay 29, 2013Budesonide CapsulesFailed Dissolution Specifications: Routine stability testing at the 12-month interval yielded an out-of-specification (OOS) result for dissolution testing.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-452-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-451-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-450-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-449-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-448-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-447-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-446-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-445-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.200 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-444-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.175 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-443-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.150 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-442-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.137 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-441-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.125 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-440-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.112 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-439-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.100 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-438-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.088 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-437-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-436-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.075 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-435-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-434-2013Class IITerminatedMay 29, 2013Lloyd Thyro-Tab 0.050 mgcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-433-2013Class IITerminatedMay 29, 2013LevothroidcGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected.Lloyd Inc. of Iowa · D-432-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-431-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-430-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-429-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-428-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-427-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-426-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-425-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-424-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-423-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-422-2013Class IITerminatedMay 29, 2013LevoxylSubpotent Drug: The products were below specification for potency at the expiry stability point.King Legacy, a wholly owned subsidiary of Pfizer · D-421-2013Class IIITerminatedMay 29, 2013Lamisil ATLabeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.Novartis Consumer Health · D-420-2013Class IIITerminatedMay 29, 2013Rite Aid brand Maximum Strength Tussin Cough & Cold Mucus Relief CFPresence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. If the product is shaken or warmed the white...Aaron Industries Inc · D-419-2013Class IIITerminatedMay 22, 2013BUCALSEPSubpotent; Cetylpyridinum ChlorideHi-Tech Pharmacal Co., Inc. · D-418-2013

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.